Amgen 2007 Annual Report Download - page 73

In addition to these properties, we have undeveloped land at certain locations, principally in Thousand Oaks,
California; Longmont, Colorado; Louisville, Kentucky; Allentown, Pennsylvania; West Greenwich, Rhode Is-
land; Seattle and Bothell, Washington and Juncos, Puerto Rico, to accommodate future expansion, as required.
Also, we purchased land in Ireland in 2006 for the construction of a process development, bulk manufacturing,
formulation, fill and finish facility. We subsequently made decisions resulting in indefinitely postponing this
project, but have retained ownership of the land. Excluded from the table above are leased properties that have
been abandoned and certain buildings that have been closed as part of our restructuring plan as further described
in Note 2, “Restructuring” to the Consolidated Financial Statements. In addition, leased facilities in Japan are
excluded from the table above, which will be disposed of in connection with Takeda acquiring our subsidiary in
Japan.
We believe our facilities are suitable for their intended use and, in conjunction with our third-party contract-
ing manufacturing agreements, provide adequate capacity. However, our bulk manufacturing facility in Puerto
Rico currently has excess capacity due principally to declining product sales and related demand for Aranesp®
resulting from regulatory and reimbursement developments occurring throughout 2007. The Company expects
excess capacity at this Puerto Rico facility to continue through 2008. We also believe that our existing facilities,
third-party contract manufacturing agreements and our anticipated additions are sufficient to meet our expected
needs. There are no material encumbrances on our properties. (See “Item 1A. Risk Factors — We manufacture
and formulate, fill and finish substantially all our products at our Puerto Rico manufacturing facility; if sig-
nificant natural disasters or production failures occur at this facility, we may not be able to supply these
products.”,“—We rely on single third-party suppliers for some of our raw materials, medical devices and com-
ponents; if these third-parties fail to supply these items, we may be unable to supply our products.” and “—
Difficulties, disruptions or delays in manufacturing or failure to comply with manufacturing regulations may lim-
it supply of our products and limit our product sales.”)
Item 3. LEGAL PROCEEDINGS
Certain of our legal proceedings in which we are involved are discussed in Note 10, “Contingences” to our
Consolidated Financial Statements in our 2007 Form 10-K and are hereby incorporated by reference.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of our security holders during the last quarter of our fiscal year ended
December 31, 2007.
61